HANDOK Inc. (002390.KS)
KRW 12270.0
(-2.54%)
KRW 12270.0
(-2.54%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 35.06 Billion KRW | -14.94% |
| 2022 | 50.25 Billion KRW | 5.7% |
| 2021 | 49.37 Billion KRW | -43.8% |
| 2020 | 49.83 Billion KRW | -12.12% |
| 2019 | 75.45 Billion KRW | 122.09% |
| 2018 | 35.11 Billion KRW | 18.8% |
| 2017 | 15.6 Billion KRW | 330.78% |
| 2016 | 18.42 Billion KRW | -62.6% |
| 2015 | 20.39 Billion KRW | -12.44% |
| 2014 | 23.38 Billion KRW | -19.72% |
| 2013 | 18.52 Billion KRW | 23.8% |
| 2012 | 21.82 Billion KRW | -33.3% |
| 2011 | 31.71 Billion KRW | -13.87% |
| 2010 | 38.07 Billion KRW | 20.3% |
| 2009 | 32.15 Billion KRW | 53.08% |
| 2008 | 20.2 Billion KRW | -43.65% |
| 2007 | 36.35 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -2.35 Billion KRW | 273.43% |
| 2024 Q1 | 10.52 Billion KRW | 792.82% |
| 2024 Q2 | 7.61 Billion KRW | -90.89% |
| 2023 Q2 | 5.22 Billion KRW | -35.31% |
| 2023 Q1 | 8.08 Billion KRW | -73.2% |
| 2023 FY | - KRW | -14.94% |
| 2023 Q3 | 8.1 Billion KRW | 55.03% |
| 2023 Q4 | 3.52 Billion KRW | -56.47% |
| 2022 Q3 | -265.04 Million KRW | -128.0% |
| 2022 Q2 | 946.59 Million KRW | -91.27% |
| 2022 FY | - KRW | 5.7% |
| 2022 Q4 | 30.15 Billion KRW | 11476.34% |
| 2022 Q1 | 10.83 Billion KRW | 28.01% |
| 2021 Q3 | 6.16 Billion KRW | -49.16% |
| 2021 Q1 | 12.23 Billion KRW | -56.37% |
| 2021 Q2 | 12.13 Billion KRW | -0.84% |
| 2021 Q4 | 8.46 Billion KRW | 37.23% |
| 2021 FY | - KRW | -43.8% |
| 2020 FY | - KRW | -12.12% |
| 2020 Q1 | 5.46 Billion KRW | -83.09% |
| 2020 Q2 | 9.5 Billion KRW | 73.71% |
| 2020 Q4 | 28.04 Billion KRW | 6.3% |
| 2020 Q3 | 26.38 Billion KRW | 177.67% |
| 2019 Q1 | 15.24 Billion KRW | 533.15% |
| 2019 Q3 | 28.98 Billion KRW | 1105.22% |
| 2019 Q4 | 32.33 Billion KRW | 11.57% |
| 2019 FY | - KRW | 122.09% |
| 2019 Q2 | 2.4 Billion KRW | -84.23% |
| 2018 Q2 | 6.93 Billion KRW | -49.5% |
| 2018 Q4 | 2.4 Billion KRW | -80.72% |
| 2018 FY | - KRW | 18.8% |
| 2018 Q1 | 13.72 Billion KRW | 3.32% |
| 2018 Q3 | 12.49 Billion KRW | 80.2% |
| 2017 Q4 | 13.28 Billion KRW | 9.83% |
| 2017 FY | - KRW | 330.78% |
| 2017 Q3 | 12.09 Billion KRW | 903.73% |
| 2017 Q2 | -1.5 Billion KRW | -204.63% |
| 2017 Q1 | 1.43 Billion KRW | 247.01% |
| 2016 Q4 | 414.54 Million KRW | -82.73% |
| 2016 Q1 | 4.02 Billion KRW | -70.26% |
| 2016 FY | - KRW | -62.6% |
| 2016 Q2 | -65.5 Million KRW | -101.63% |
| 2016 Q3 | 2.4 Billion KRW | 3764.38% |
| 2015 Q3 | 1.93 Billion KRW | 2.81% |
| 2015 Q1 | 1.23 Billion KRW | 0.0% |
| 2015 FY | - KRW | -12.44% |
| 2015 Q2 | 1.87 Billion KRW | 52.5% |
| 2015 Q4 | 13.53 Billion KRW | 601.49% |
| 2014 FY | - KRW | -19.72% |
| 2014 Q3 | 3.07 Billion KRW | -50.17% |
| 2014 Q2 | 6.17 Billion KRW | -39.1% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q1 | 10.14 Billion KRW | -34.16% |
| 2013 Q1 | 3.44 Billion KRW | 117.38% |
| 2013 FY | - KRW | 23.8% |
| 2013 Q2 | 4 Billion KRW | 16.27% |
| 2013 Q3 | 4.33 Billion KRW | 8.38% |
| 2013 Q4 | 15.41 Billion KRW | 255.13% |
| 2012 Q4 | 1.58 Billion KRW | -73.46% |
| 2012 Q1 | 6.52 Billion KRW | 0.0% |
| 2012 Q2 | 6 Billion KRW | -7.98% |
| 2012 Q3 | 5.96 Billion KRW | -0.56% |
| 2012 FY | - KRW | -33.3% |
| 2011 FY | - KRW | -13.87% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 7.35 Billion KRW | -21.49% |
| 2011 Q2 | 9.36 Billion KRW | -3.69% |
| 2011 Q1 | 9.72 Billion KRW | 58.13% |
| 2010 Q1 | 7.4 Billion KRW | -12.2% |
| 2010 FY | - KRW | 20.3% |
| 2010 Q2 | 11.66 Billion KRW | 57.48% |
| 2010 Q3 | 11.94 Billion KRW | 2.37% |
| 2010 Q4 | 6.14 Billion KRW | -48.53% |
| 2009 Q1 | 5.82 Billion KRW | 619.72% |
| 2009 Q3 | 8.48 Billion KRW | -2.51% |
| 2009 Q2 | 8.69 Billion KRW | 49.23% |
| 2009 Q4 | 8.43 Billion KRW | -0.49% |
| 2009 FY | - KRW | 53.08% |
| 2008 Q2 | 7.52 Billion KRW | 43.31% |
| 2008 Q3 | 6.59 Billion KRW | -12.46% |
| 2008 Q4 | 810 Million KRW | -87.71% |
| 2008 FY | - KRW | -43.65% |
| 2008 Q1 | 5.25 Billion KRW | -48.42% |
| 2007 Q4 | 10.18 Billion KRW | 12.11% |
| 2007 Q3 | 9.08 Billion KRW | 2.55% |
| 2007 Q2 | 8.86 Billion KRW | 15.34% |
| 2007 Q1 | 7.68 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -621.784% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 75.194% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 154.761% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3482.938% |
| Yuhan Corporation | 127.43 Billion KRW | 72.482% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 6.541% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 261.69% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 89.155% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -602.694% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -131.95% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -925.05% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -674.715% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 1.183% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -621.784% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 289.839% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -434.964% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 171.141% |
| JW Holdings Corporation | 187.88 Billion KRW | 81.336% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 168.452% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 87.636% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.697% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 194.604% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -165.464% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -196.475% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -87.976% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -621.784% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 36.211% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 78.736% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.697% |
| Yuhan Corporation | 127.43 Billion KRW | 72.482% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -4.752% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -358.398% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 54.476% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.697% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 4.279% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 50.457% |
| CKD Bio Corp. | -1.63 Billion KRW | 2250.746% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 29.575% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -7.694% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 4.737% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 194.604% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 43.699% |
| Boryung Corporation | 114.28 Billion KRW | 69.317% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 214.716% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -131.95% |
| JW Lifescience Corporation | 50.82 Billion KRW | 31.011% |